BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report

BackgroundMutations in the human breast cancer susceptibility gene 2 (breast cancer 2, BRCA2) increase the risk of breast, ovarian and other cancers. Olaparib, an oral poly[adenosine diphosphate (ADP)–ribose] polymerase (PARP) inhibitor, is usually prescribed to treat BRCA mutated tumors, especially...

Full description

Bibliographic Details
Main Authors:	Zhujun Chen, Kang Wang, Lintao Zhao, Liang Gong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	Olaparib lung squamous cell carcinoma PD-1 inhibitor BRCA2 mutation case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1190100/full

Similar Items

Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple‐negative breast cancer
by: Xia‐Bo Shen, et al.
Published: (2024-04-01)

Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation
by: Qing Zhang, et al.
Published: (2024-02-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01)

Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib
by: Vlad-Adrian Afrăsânie, et al.
Published: (2024-08-01)

BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report
by: Takumi Motohashi, et al.
Published: (2024-03-01)

Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive <i>BRCA</i>-related breast cancer
by: A. I. Stukan, et al.
Published: (2022-05-01)

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
by: José Enrique Alés-Martínez, et al.
Published: (2024-10-01)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
by: Elisena Franzese, et al.
Published: (2019-11-01)

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
by: Anke Kröcher, et al.
Published: (2023-10-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

Treatment outcomes of patients with BRCA-mutated, recurrent ovarian cancer in University Hospital Center Split
by: Branka Petrić-Miše, et al.
Published: (2022-01-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
by: Alfonso Cortés, et al.
Published: (2024-12-01)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
by: Inês Costa, et al.
Published: (2022-05-01)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
by: Yamin Shu, et al.
Published: (2022-08-01)

Experience in treating BRCA-associated breast cancer. The BRCA-history of a family
by: A. V. Sultanbaev, et al.
Published: (2021-08-01)

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
by: Luis Cordero Puentes, et al.
Published: (2018-05-01)

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program
by: A. A. Rumyantsev, et al.
Published: (2022-06-01)

Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation
by: Xin Sun, et al.
Published: (2022-08-01)

BRCA testing and management of BRCA-mutated early-stage breast cancer: a comprehensive statement by expert group from GCC region
by: Humaid O. Al-Shamsi, et al.
Published: (2024-04-01)

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
by: Sijin Chen, et al.
Published: (2024-08-01)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
by: Víctor Albarrán, et al.
Published: (2023-05-01)

Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer
by: L. V. Bolotina, et al.
Published: (2022-06-01)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
by: Caixia Li, et al.
Published: (2022-12-01)

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
by: Tomao F, et al.
Published: (2020-07-01)

Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature
by: Minghan Song, et al.
Published: (2023-05-01)

Acquired Treatment Resistance in a Patient with Metastatic PD-L1-Positive Breast Cancer and Germline BRCA1 Mutation
by: Toko Kumeta, et al.
Published: (2023-07-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature
by: Gonzalo Lendinez-Sanchez, et al.
Published: (2024-08-01)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
by: Tong Wu, et al.
Published: (2023-08-01)

Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases
by: Kazuki Asazuma, et al.
Published: (2024-07-01)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
by: Pramod Kumar Julka, et al.
Published: (2020-02-01)

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
by: Taotao Zhou, et al.
Published: (2022-07-01)

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance
by: Rachel W Anantha, et al.
Published: (2017-04-01)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
by: Jeffrey C.H. Goh, et al.
Published: (2022-08-01)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
by: Brigida Anna Maiorano, et al.
Published: (2023-04-01)